147 related articles for article (PubMed ID: 36101483)
1. A post-mortem analysis of tenofovir, lamivudine, efavirenz and fluconazole penetration in female genital tissues.
Wang F; Namuju OC; Pastick KA; Abdusalaamu K; Mishra U; Collins L; Boulware DR; Lukande R; Meya DB; Nicol MR
J Antimicrob Chemother; 2022 Oct; 77(11):3180-3186. PubMed ID: 36101483
[TBL] [Abstract][Full Text] [Related]
2. Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis.
Nicol MR; Eneh P; Nakalega R; Kaiser T; Kabwigu S; Isingel E; Beksinska M; Sykes C; Fowler MG; Brown TT; Staley C; Kiweewa Matovu F
Clin Infect Dis; 2020 Apr; 70(8):1717-1724. PubMed ID: 31131846
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
Dumond JB; Nicol MR; Kendrick RN; Garonzik SM; Patterson KB; Cohen MS; Forrest A; Kashuba AD
Clin Pharmacokinet; 2012 Dec; 51(12):809-22. PubMed ID: 23044523
[TBL] [Abstract][Full Text] [Related]
4. Post-mortem analysis of dolutegravir, tenofovir, lamivudine and efavirenz penetration in multiple CNS compartments.
Wang F; Rademeyer K; Namuju OC; Abdusalaamu K; Fisher J; Meya DB; McRae M; Boulware DR; Lukande R; Nicol MR
J Infect Dis; 2024 Jun; ():. PubMed ID: 38900910
[TBL] [Abstract][Full Text] [Related]
5. COMPARISON OF THAI GOVERNMENT MANUFACTURED TENOFOVIR (TENOFOVIR GPO300) WITH PRIVATELY MANUFACTURED TENOFOVIR (VIREAD) USED ALONG WITH LAMIVUDINE AND EFAVIRENZ TO TREAT THAI HIV PATIENTS.
Manosuthi W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Southeast Asian J Trop Med Public Health; 2015 Jan; 46(1):19-26. PubMed ID: 26513901
[TBL] [Abstract][Full Text] [Related]
6. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.
Palombi L; Pirillo MF; Marchei E; Jere H; Sagno JB; Luhanga R; Floridia M; Andreotti M; Galluzzo CM; Pichini S; Mwenda R; Mancinelli S; Marazzi MC; Vella S; Liotta G; Giuliano M
J Antimicrob Chemother; 2016 Apr; 71(4):1027-30. PubMed ID: 26679247
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz.
Harrington BJ; DiPrete BL; Jumbe AN; Ngongondo M; Limarzi L; Wallie SD; Chagomerana MB; Hosseinipour MC;
Trop Med Int Health; 2019 Oct; 24(10):1221-1228. PubMed ID: 31381233
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV.
Hsieh E; Fraenkel L; Han Y; Xia W; Insogna KL; Yin MT; Zhu T; Cheng X; Li T
AIDS; 2016 Jul; 30(12):1935-42. PubMed ID: 27124896
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal Fluid and Brain Tissue Penetration of Tenofovir, Lamivudine, and Efavirenz in Postmortem Tissues with Cryptococcal Meningitis.
Nicol MR; Pastick KA; Taylor J; Namuju OC; Rhein J; Williams DA; Meya DB; Boulware DR; Lukande R
Clin Transl Sci; 2019 Sep; 12(5):445-449. PubMed ID: 31207069
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
Avihingsanon A; Maek-A-Nantawat W; Gatechompol S; Sapsirisavat V; Thiansanguankul W; Sophonphan J; Thammajaruk N; Ubolyam S; Burger DM; Ruxrungtham K
Int J Infect Dis; 2017 Aug; 61():89-96. PubMed ID: 28627427
[TBL] [Abstract][Full Text] [Related]
13. Vaginal microbiome, antiretroviral concentrations, and HIV genital shedding in the setting of hormonal contraception initiation in Malawi.
Lantz AM; Cottrell ML; Corbett AH; Chinula L; Kourtis AP; Nelson JAE; Tegha G; Hurst S; Gajer P; Ravel J; Haddad LB; Tang JH; Nicol MR
AIDS; 2023 Nov; 37(14):2185-2190. PubMed ID: 37877275
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Efavirenz 600 mg Once Daily During Pregnancy and Post Partum in Ghanaian Women Living With HIV.
Lartey M; Kenu E; Lassey A; Ntumy M; Ganu V; Sam M; Boamah I; Gilani FS; Yang H; Burch GM; Norman J; Peloquin CA; Kwara A
Clin Ther; 2020 Sep; 42(9):1818-1825. PubMed ID: 32811669
[TBL] [Abstract][Full Text] [Related]
16. Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
Calza L; Magistrelli E; Danese I; Colangeli V; Borderi M; Bon I; Re MC; Mancini R; Conti M; Motta R; Viale P
Curr HIV Res; 2016; 14(1):61-70. PubMed ID: 26531764
[TBL] [Abstract][Full Text] [Related]
17. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Bosch B; Akpomiemie G; Chandiwana N; Sokhela S; Hill A; McCann K; Qavi A; Mirchandani M; Venter WDF
Clin Infect Dis; 2023 Apr; 76(8):1492-1495. PubMed ID: 36519389
[TBL] [Abstract][Full Text] [Related]
18. The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy.
Donahue Carlson R; Sheth AN; Read TD; Frisch MB; Mehta CC; Martin A; Haaland RE; Patel AS; Pau CP; Kraft CS; Ofotokun I
J Infect Dis; 2017 Nov; 216(8):990-999. PubMed ID: 29029138
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
Naicker N; Naidoo A; Werner L; Garrett N; Majola N; Asari V; Baxter C; Grobler A; Karim QA; Karim SSA
Antivir Ther; 2017; 22(4):287-293. PubMed ID: 27835613
[TBL] [Abstract][Full Text] [Related]
20. Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.
Bednasz CJ; Venuto CS; Ma Q; Daar ES; Sax PE; Fischl MA; Collier AC; Smith KY; Tierney C; Acosta EP; Mager DE; Morse GD;
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30642925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
